A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)

This study has been terminated.
(The study was terminated prematurely when the decision was made that ocrelizumab was not likely to benefit this patient population.)
Sponsor:
Collaborator:
Roche Pharma AG
Information provided by (Responsible Party):
Genentech
ClinicalTrials.gov Identifier:
NCT00539838
First received: October 3, 2007
Last updated: January 17, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2011
  Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: January 17, 2013